Recursion Pharmaceuticals, Inc. (RXRX) Gross profit 2020–2025
Recursion Pharmaceuticals, Inc. (RXRX) annual gross profit history from SEC filings — each fiscal year as reported.
$3.7MFY2025 · since FY2020: $4.0M → $3.7M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | $3.7M | -72.6% |
| FY2024 | $13.6M | +584.2% |
| FY2023 | $2.0M | +123.6% |
| FY2022 | -$8.4M | -182.8% |
| FY2021 | $10.2M | +156.9% |
| FY2020 | $4.0M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More RXRX financial trends
RXRX RevenueRXRX Net incomeRXRX Net marginRXRX Gross marginRXRX Operating incomeRXRX Operating marginRXRX Operating cash flowRXRX Free cash flowRXRX Capital expendituresRXRX Return on equityRXRX Stock buybacksRXRX Dividends paidRXRX Total assetsRXRX Total liabilitiesRXRX Shareholders’ equityRXRX overview →